Zobrazeno 1 - 10 of 55 pro vyhledávání: '"Carolyn M. Setze"'
2
Resistance characterization of hepatitis C virus genotype 2 from Japanese patients treated with ombitasvir and paritaprevir/ritonavir
Autor: Katia Alves, Rebecca Redman, Tatyana Dekhtyar, Margaret Burroughs, Gretja Schnell, Lino Rodrigues-Jr, Rakesh Tripathi, Thomas Reisch, Michelle Irvin, Kazuaki Chayama, Tami Pilot-Matias, Preethi Krishnan, Christine Collins, Jill Beyer, Hiromitsu Kumada, Carolyn M. Setze
Publikováno v: Journal of Medical Virology
Treatment of HCV genotype (GT) 2-infected Japanese patients with paritaprevir (NS3/4A inhibitor boosted with ritonavir) and ombitasvir (NS5A inhibitor) without ribavirin for 12 weeks in the phase 2 study M12-536, and with ribavirin for 16 weeks in ph
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::041bb678ff7c495d201d838afa26805e
https://doi.org/10.1002/jmv.24923
Zobrazit plný text záznamu
3
Randomized Phase 3 Trial of Ombitasvir/Paritaprevir/Ritonavir and Ribavirin for Hepatitis C Virus Genotype 2-Infected Japanese Patients
Autor: Tami Pilot-Matias, Koji Kato, Hiromitsu Kumada, Carolyn M. Setze, Margaret Burroughs, Kazuaki Chayama, Lino Rodrigues, Fumitaka Suzuki, Xinyan Zhang, Rebecca Redman, Katia Alves, Ken Sato, Hidenori Toyoda
Publikováno v: Advances in Therapy. 34:1449-1465
In Japan, hepatitis C virus (HCV) genotype (GT) 2 accounts for approximately 32% of HCV infections. Limited treatment options exist in Japan for HCV GT2-infected patients. GIFT-II was a phase 3, randomized, open-label study evaluating the efficacy an
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::846f1c6635d20660c3055f45fdd3de3c
https://doi.org/10.1007/s12325-017-0506-y
Zobrazit plný text záznamu
4
Analysis of Hepatitis C Virus Genotype 1b Resistance Variants in Japanese Patients Treated with Paritaprevir-Ritonavir and Ombitasvir
Autor: Jill Beyer, Lino Rodrigues, Carolyn M. Setze, Rakesh Tripathi, Rebecca Redman, Thomas Reisch, Margaret Burroughs, Xinyan Zhang, Tami Pilot-Matias, Christine Collins, Kazuaki Chayama, Preethi Krishnan, Hiromitsu Kumada, Gretja Schnell
Publikováno v: Antimicrobial Agents and Chemotherapy
Treatment of HCV genotype 1b (GT1b)-infected Japanese patients with paritaprevir (NS3/4A inhibitor boosted with ritonavir) and ombitasvir (NS5A inhibitor) in studies M12-536 and GIFT-I demonstrated high sustained virologic response (SVR) rates. The v
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::02fd9cd6138bac65bdad789ad2dd0dcd
http://europepmc.org/articles/PMC4750684
Zobrazit plný text záznamu
5
Randomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for hepatitis C virus genotype 1b–infected Japanese patients with or without cirrhosis
Autor: Kiyohide Kioka, Kazuaki Chayama, Regis A. Vilchez, Kenji Ikeda, Rebecca Redman, Hiromitsu Kumada, Hidenori Toyoda, Margaret Burroughs, Tami Pilot-Matias, Yasushi Matsuzaki, Ken Sato, Carolyn M. Setze, Lino Rodrigues, Yoshiyasu Karino, Meenal Patwardhan, Fumitaka Suzuki
Publikováno v: Hepatology (Baltimore, Md.)
GIFT‐I is a phase 3 trial evaluating the efficacy and safety of a 12‐week regimen of coformulated ombitasvir (OBV)/paritaprevir (PTV)/ritonavir (r) for treatment of Japanese hepatitis C virus genotype 1b–infected patients. It consists of a doub
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a0f52fac456c1f5ae85307802de6a274
https://doi.org/10.1002/hep.27972
Zobrazit plný text záznamu
6
A Randomized, Double-Blind Study of Fenofibric Acid Plus Rosuvastatin Compared With Rosuvastatin Alone in Stage 3 Chronic Kidney Disease
Autor: James C. Stolzenbach, Aditya Lele, Maureen T. Kelly, Debra L. Weinstein, Laura A. Williams, Carolyn M. Setze, Dawn M. Carlson, Kim M. Burns
Publikováno v: Clinical Therapeutics. 35:1186-1198
Patients with chronic kidney disease (CKD) often have mixed dyslipidemia and high cardiovascular disease risk. Although statins reduce LDL-C, adding a fibrate may further improve lipid parameters.This multicenter, randomized study evaluated the short
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::392f69f12549442f9ad2dc1004a618ea
https://doi.org/10.1016/j.clinthera.2013.06.013
Zobrazit plný text záznamu
7
Attainment of goal/desirable lipid levels in patients with mixed dyslipidemia after 12 weeks of treatment with fenofibric acid and rosuvastatin combination therapy: A pooled analysis of controlled studies
Autor: Aditya Lele, Maureen T. Kelly, Robert S. Rosenson, Michael H. Davidson, Peter B. Jones, Kamlesh M. Thakker, Eli M. Roth, Carolyn M. Setze
Publikováno v: Journal of Clinical Lipidology. 6:534-544
Goal/desirable lipid levels are underachieved in patients with mixed dyslipidemia. These patients may have substantial residual risk of cardiovascular disease even while receiving optimal LDL-C-lowering therapy and may require additional therapy to i
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9b5cd906ef8cdda922de4ace4a03d1e9
https://doi.org/10.1016/j.jacl.2012.02.002
Zobrazit plný text záznamu
8
Study Design, Rationale, and Baseline Characteristics: Evaluation of Fenofibric Acid on Carotid Intima-Media Thickness in Patients with Type IIb Dyslipidemia with Residual Risk in Addition to Atorvastatin Therapy (FIRST) Trial
Autor: James C. Stolzenbach, Kevin C. Maki, Christie M. Ballantyne, Dawn M. Carlson, Carolyn M. Setze, Robert S. Rosenson, Michael H. Davidson, Stephen J. Nicholls
Publikováno v: Cardiovascular Drugs and Therapy
Purpose Elevated triglycerides (TG) and low high-density lipoprotein cholesterol (HDL-C) levels contribute to cardiovascular disease risk and can be effectively treated with fenofibric acid. A trial is under way to evaluate the effect of once-daily f
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b173dfdf3d9b7aa59eab3b1c711c58e
https://doi.org/10.1007/s10557-012-6395-z
Zobrazit plný text záznamu
9
One-Year Efficacy and Safety of Rosuvastatin + Fenofibric Acid Combination Therapy in Patients with Mixed Dyslipidemia
Autor: Carolyn M. Setze, Michael H. Davidson, Maureen T. Kelly, Keith C. Ferdinand
Publikováno v: American Journal Cardiovascular Drugs. 12:117-125
Statins are the standard-of-care therapy for reducing low-density lipoprotein cholesterol (LDL-C) levels; however, combination with other lipid-modifying agents may be necessary to normalize lipid profiles in patients with mixed dyslipidemia who, in
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d0673ebe6ff998ae03742e6d4b7c625
https://doi.org/10.2165/11597940-000000000-00000
Zobrazit plný text záznamu
10
Evaluating optimal lipid levels in patients with mixed dyslipidemia following short- and long-term treatment with fenofibric acid and statin combination therapy: a post hoc analysis
Autor: Maureen T. Kelly, Kamlesh M. Thakker, Carolyn M. Setze, Syed M. Mohiuddin
Publikováno v: Current Medical Research and Opinion. 27:1067-1078
To evaluate the achievement of individual and combined lipid and lipoprotein/biomarker targets as specified by treatment guidelines with the combination of fenofibric acid and statin therapy in patients with mixed dyslipidemia.Data for the post hoc a
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b88b3c70b234c0a672606d4a6fbab14f
https://doi.org/10.1185/03007995.2011.569018
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje